JCVI: Giving / Tuesday
 
 
Section Banner

Invest in Jaw-Dropping Science

The Next Breakthrough in Treating Oral Disease Might Come from Bacteria


Most people think of bacteria as the enemy, but scientists at the J. Craig Venter Institute (JCVI) are exploring ways to harness bacteria and phages (the viruses that infect bacteria) as a new way to fight infection. JCVI scientist, Anna Edlund, Ph.D., is leading one of our efforts to understand the human oral microbiome and learn what role bacteria play in both oral health and disease.


The Edlund research group at the Department of Genomic Medicine, JCVI. From left to right: Dr. Gajender Aleti, Visiting Scientist Jamie Zhang, Dr. Anna Edlund, and Dr. Xiaoyu Tang.

Inflammatory gum disease (gingivitis/periodontal disease) and tooth decay are not only the two biggest threats to oral health, but they also contribute to systemic diseases such as diabetes and cardiovascular disease. Oral health concerns begin early, with cavities being one of the most chronic conditions in the United States in children and adolescents.

Dr. Edlund wants to determine the function of the hundreds of microbes living in the mouth, especially their relation to diseases, and identify non-invasive treatments and therapies specific to oral disease.

The Phage Cocktail Approach


Bacteriophages are viruses that infect and thrive inside bacteria. They are one of the most abundant biological entities on earth and are found everywhere there are bacteria. Because of their ability to attack bacteria, phages have been used as antibiotics for nearly a century in the former Soviet Union, Central Europe, and France. Given the troubling rise of antibiotic resistance, phage therapy could be a new weapon in the war against infection.

The phage therapy approach focuses on developing a potential treatment to kill specific oral bacterial pathogens, removing harmful biofilms, and re-colonizing the mouth with healthy bacteria to prevent re-growth.

To do this, we will first isolate and purify a diverse community of phage. Specific phage activity will be cataloged, and then tested individually against known disease-causing oral bacteria. Cocktails of effective phages will be tested against a broader group of bacteria. A future goal of the project is to then test the phage cocktails in mouse models to confirm viable candidates to move into clinical testing in humans.

The Healthy Bacteria Approach


While probiotics are widely used globally, currently none of the available probiotics on the market have been scientifically proven to prevent or treat oral disease. A goal of the “healthy bacteria approach” is to explore and enhance understanding of interactions between probiotic bacteria in oral biofilms, as well as between bacteria and human host cells.

Recently, Dr. Edlund’s laboratory discovered about 5,600 novel gene clusters from the human oral microbiome that are genetically similar to known natural products. Natural products play important roles in mediating communication between human and bacterial cells, suggesting that the human mouth is a highly diverse and underexplored environment for the discovery of novel therapeutics. In this project, the team will apply their new knowledge to formulate probiotics that target specific pathogens, such as those that cause tooth decay and thrush.

We believe that this research will result in an arsenal of oral bacteria that produce novel natural products which play a major role in promoting oral health. This, in turn, will lead to future studies, including activity screening in animal models, and clinical testing of probiotics in humans.

Invest in discovery today. Your donation enables scientists like Dr. Edlund to transform the way human disease is prevented and treated.

Want more information?


Contact the Development Office at development@jcvi.org.

The J. Craig Venter Institute (JCVI) did not provide any goods or services to you in whole or in partial consideration for the aforementioned contribution. The full amount of your contribution is tax deductible subject to applicable laws and IRS regulations. JCVI is a 501(c)3 with the federal tax identification number 52-1842938. This acknowledgement is provided pursuant to section 170(f)(8) of the Internal Revenue Code.